Содержание
- 2. INFLUENZA is an acute infectious disease which occurs in epidemics and is caused by a virus,
- 3. Influenza takes the leading position in the human pathology. The main thing is that besides relatively
- 4. History The first documented pandemic of influenza (retrospectively - influenza type A virus) occurred in 1889.
- 5. History In 1890 M.I. Afanasiev and in 1892 the German doctor R. Pfeiffer isolated small bacilli
- 6. Etiology The family Orthomyxoviridae comprises: influenza A, B, C. Influenza A viruses can infect a variety
- 7. Etiology The virions are spherical 80-120 nm in diameter. They have a nucleocapsid comprising RNA, RNA-polymerase.
- 8. Etiology Influenza viruses bind to cells by the haemagglutinin interacting with membrane recep-tors. Neuraminidase activity is
- 9. One of the most prominent features of the influenza viruses is their ability to change antigenically
- 10. Nomenclature. The World Health Organization system of nomenclature includes: the host of origin; geographical origin, strain
- 11. A / Scotland / 42/89 (H3N2)
- 12. Nomenclature There are 15 different H antigens and 9 N antigens. But only H1-H3 and N1-N2
- 13. Nomenclature However, in 1997 an outbreak, with high case mortality, occurred in humans in Hong Kong;
- 14. Physical characteristics The influenza viruses withstands slow drying at room temperature on articles such as blankets
- 15. Physical characteristics Exposure to heat for 30 min at 56°C is sufficient to inactivate most strains.
- 16. Epidemiology Epidemics, which must have been caused by influenza viruses, have been described for over 2000
- 17. Epidemiology In 1933 Christopher Andrewes and others isolated influenza A virus. Continued isolation studies and analysis
- 18. Epidemiology The mayor pandemics are associated with antigenic shifts – when the viral H or N,
- 19. Epidemiology Until 1977, when H1N1 reappeared, it was the rule that when a “new” virus appeared,
- 20. Epidemiology Influenza B viruses do not undergo antigenic shift as there is no animal reservoir and,
- 21. Epidemiology A sick person is the only source of the disease. The virus quickly multiplies in
- 22. Epidemiology The influenza infection is spread with the help of small particle aerosol dispersion. The mechanism
- 23. Epidemiology The viable influenza virus can live and be infectious in the air for 2 -3
- 24. Epidemiology The speed of influenza spreading depends on the speed of people moving on the territory.
- 25. Pathogenesis Pathogencity of influenza viruses is multifactirial and may involve viral, host and environment factors. After
- 26. Pathogenesis The virus multiplication cycle lasts 7-10 hours. Every virion which penetrated a cell gives birth
- 27. Pathogenesis The cell, in which virus reproduces, produces and secretes interferon. This interferon gets into the
- 28. Pathogenesis The cells affected by a virus are rejected and the products of their decomposition are
- 29. Pathogenesis When the process spreads in the lung tissue, there are signs of general edema with
- 30. Pathogenesis Under these conditions the influenza virus easily penetrates the blood and virusemia develops. However, virusemia
- 31. Pathogenesis Besides, it is a fact that even in the mild cases of the disease there
- 32. Pathogenesis The earliest response is the synthesis and release of interferons from the infected cells: these
- 33. Clinical features. In classic influenza A: The incubation period is short, 2 days, but it may
- 34. Clinical features The incubation period at influenza in short: from several hours to 2 days. Its
- 35. Clinical features The first symptoms are chilliness, high temperature, headaches, dizziness, a syncope condition, malaise, pains
- 36. Clinical features The main physical finding is pyrexia, which rises rapidly to a peak of 38-41°C
- 37. Clinical features Adynamia, malaise can be considerable and are manifested since the first day of the
- 38. Clinical features of influenza
- 39. Clinical features Many patients have both upper and lower respiratory tract infection, ofen with a troublesome,
- 40. Clinical features The affection of the upper respiratory tracts is accompanied with hyperemia and swelling of
- 41. Clinical features During fauces examination hyperemia of the tonsils, uvula palatina and posterior wall of the
- 42. Clinical features Diverse changes in the cardiovascular system have been described. The pulse very often corresponds
- 43. Clinical features There are various affections of the nervous system during the influenza infection. The functional
- 44. Clinical features. In classic influenza B: Symptoms closely resemble those associated with influenza A infection, consisting
- 45. Clinical features. In classic influenza C: Clinically, influenza C causes an afebrile upper respiratory tract infection
- 46. Complications of influenza: Primary influenza pneumonia may occur, especially in young adults during an outbreak, and
- 47. The changes in the hemogram are manifested as leukopenia or normocytosis. If there are no complications
- 48. Laboratory diagnosis The virusological methods of diagnostics are used to isolate and identify the influenza virus.
- 49. Laboratory diagnosis The serological diagnostics of influenza ensures an accurate determination of etiology by revealing the
- 50. Laboratory diagnosis The immunefluorescent method is recommended as one of the reliable means of quick deciphering
- 51. immune fluorescent method The essence of the immune fluorescent method is in specific reactions of antigen-antibody
- 52. Treatment During the epidemics 10-25% of the adult population fall ill with influenza, 1-2% of them
- 53. Treatment Even in case of a moderate severe influenza form together with an unfavorable premorbid condition
- 54. Treatment Oral amantadine hydrochloride was introduced in the early 1980s, followed later by a derivative, rimantadine.
- 55. Treatment The usage of rimantadinum is quite effective especially during the first days of the disease.
- 56. "Rimantadinum" appoints under the circuit: 1-st day - on 100 mg (2 tablets) 3 times; 2-nd
- 57. More recently neuraminidase inhibitor Oseltamivir. Oseltamivir uses influenza A, B and H5N1 infections. It can reduce
- 58. There is fast elimination of intoxication and noticeable improvement of the patients’ general condition observed when
- 59. Such preparations as 5-20% albumin solution, native or dried plasma 150-200 ml, haemodesum 200 ml, rheopolyglucinum
- 61. Скачать презентацию